Dowling & Yahnke LLC increased its position in shares of Eli Lilly And Co (NYSE:LLY) by 0.7% during the second quarter, HoldingsChannel.com reports. The fund owned 59,617 shares of the company’s stock after acquiring an additional 390 shares during the period. Dowling & Yahnke LLC’s holdings in Eli Lilly And Co were worth $6,605,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the stock. South Street Advisors LLC increased its holdings in Eli Lilly And Co by 7.8% during the 2nd quarter. South Street Advisors LLC now owns 98,140 shares of the company’s stock worth $10,873,000 after acquiring an additional 7,060 shares during the period. Murphy Capital Management Inc. increased its holdings in shares of Eli Lilly And Co by 15.2% in the 2nd quarter. Murphy Capital Management Inc. now owns 19,635 shares of the company’s stock worth $2,175,000 after buying an additional 2,591 shares during the last quarter. Blue Fin Capital Inc. increased its holdings in shares of Eli Lilly And Co by 0.9% in the 2nd quarter. Blue Fin Capital Inc. now owns 11,619 shares of the company’s stock worth $1,287,000 after buying an additional 101 shares during the last quarter. Bellecapital International Ltd. increased its holdings in shares of Eli Lilly And Co by 4.9% in the 2nd quarter. Bellecapital International Ltd. now owns 5,369 shares of the company’s stock worth $595,000 after buying an additional 250 shares during the last quarter. Finally, AE Wealth Management LLC increased its holdings in shares of Eli Lilly And Co by 96.4% in the 2nd quarter. AE Wealth Management LLC now owns 13,721 shares of the company’s stock worth $1,520,000 after buying an additional 6,734 shares during the last quarter. 79.50% of the stock is currently owned by institutional investors and hedge funds.
In other news, CFO Joshua L. Smiley bought 426 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The stock was purchased at an average price of $118.03 per share, with a total value of $50,280.78. Following the transaction, the chief financial officer now owns 30,410 shares of the company’s stock, valued at $3,589,292.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Michael J. Harrington sold 16,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $116.72, for a total value of $1,867,520.00. Following the completion of the transaction, the vice president now directly owns 110,300 shares of the company’s stock, valued at approximately $12,874,216. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.
NYSE LLY opened at $110.51 on Friday. Eli Lilly And Co has a fifty-two week low of $97.84 and a fifty-two week high of $132.13. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50. The stock has a 50 day simple moving average of $111.06. The stock has a market cap of $105.52 billion, a PE ratio of 19.91, a P/E/G ratio of 1.91 and a beta of 0.20.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 57.99% and a net margin of 33.76%. The business had revenue of $5.64 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the business posted $1.48 EPS. The business’s revenue was up .9% on a year-over-year basis. Equities analysts forecast that Eli Lilly And Co will post 5.71 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $0.645 dividend. This represents a $2.58 annualized dividend and a yield of 2.33%. The ex-dividend date of this dividend is Wednesday, August 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 46.49%.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Bollinger Bands
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.